Tiantan Bio (600161.SS)

Executive Summary

Tiantan Bio (600161.SS) is a leading Chinese biopharmaceutical company focused on blood products and vaccines. Its core business, generating stable revenue from plasma-derived therapies such as human albumin and immunoglobulins, as well as vaccines like influenza, provides a solid financial foundation. The company operates an integrated model from plasma collection to commercialization and holds a strong position in the domestic market. Beyond its marketed portfolio, Tiantan Bio is expanding into innovative therapies. Its pipeline includes an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease (Phase 1, recruiting), endostatin for vestibular schwannoma (Phase 2 completed), and CN-105 for intracerebral hemorrhage (Phase 2, status unknown). The iPSC program represents a strategic shift into regenerative medicine, while the other candidates address unmet needs. With a robust commercial base and early-stage R&D, Tiantan Bio is poised for growth, though pipeline execution remains key to unlocking value.

Upcoming Catalysts (preview)

• H2 2026iPSC-derived cell therapy Phase 1 interim data for Parkinson's disease20% success
• 2026CN-105 Phase 2 results for intracerebral hemorrhage30% success
• 2026New blood product approval in China50% success